Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on ...

As pharmaceutical import tariffs take shape in Europe, President Donald Trump is rounding out the week by spotlighting ...

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Reported EPS is $0.2429 EPS, expectations were $0.63. Operator: Hello, and welcome to the Teva Pharmaceutical Industries ...

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...

That's the top-line finding of the latest financing report from the UK BioIndustry Association (BIA), which reveals that ...

Muted enthusiasm for this week’s US-EU trade agreement did little to dispel concerns that the US has unfinished business with Ireland’s pharmaceutical sector.